Physician profile
Harold Mermelstein
NPI 1053308429
$6,641.28
in general payments reported to CMS, 2019-2025
31 companies · $1,929 in 2025
The $1,929 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $390 · 2021: $670 · 2022: $612 · 2023: $1,232 · 2024: $1,602 · 2025: $1,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,568 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,568.08 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,041.21 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $786.65 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Galderma Laboratories, L.P. | $675.73 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Regeneron Healthcare Solutions, INC. | $553.98 | 2021-2025 | Dupixent |
| Genzyme Corporation | $533.48 | 2022-2025 | |
| Janssen Biotech, INC. | $492.77 | 2021-2025 | Tremfya, Simponi, Stelara |
| Dermavant Sciences, INC. | $434.50 | 2023-2024 | Vtama |
| Pfizer INC. | $372.36 | 2019-2025 | |
| Incyte Corporation | $361.67 | 2022-2025 | Opzelura |
| Amgen INC. | $162.63 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $155.59 | 2019-2025 | Olumiant, Ebglyss, Taltz |
| Leo Pharma INC. | $154.03 | 2021-2025 | Adbry |
| Botanix Sb INC | $140.03 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $138.03 | 2019-2024 | Jublia |
| Organon LLC | $110.96 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $99.47 | 2022-2025 | Sotyktu |
| Vyne Pharmaceuticals INC. | $96.34 | 2020-2021 | |
| Biofrontera INC. | $49.61 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $33.83 | 2023-2025 | Ycanth |
| Arcutis Biotherapeutics, INC. | $31.80 | 2023-2024 | Zoryve |
| Almirall LLC | $30.65 | 2021 | |
| Merz North America, INC. | $27.79 | 2022 | |
| Ucb, INC. | $27.54 | 2023-2025 | Bimzelx, Cimzia |
| Helsinn Therapeutics (U.S.), INC. | $27.32 | 2021-2022 | |
| Aclaris Therapeutics, INC. | $18.93 | 2019 | |
| Dermira, INC. | $17.20 | 2020 | |
| Strata Skin Sciences, INC. | $15.91 | 2024 | Xtrac |
| Mayne Pharma Commercial LLC | $14.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.49 | 2019 | |
| Stemline Therapeutics INC. | $11.75 | 2020 | |
| Kyowa Kirin, INC. | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Mermelstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.